326 related articles for article (PubMed ID: 7742721)
1. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
2. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
4. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
Tsutsumi K; Kotegawa T; Matsuki S; Tanaka Y; Ishii Y; Kodama Y; Kuranari M; Miyakawa I; Nakano S
Clin Pharmacol Ther; 2001 Aug; 70(2):121-5. PubMed ID: 11503005
[TBL] [Abstract][Full Text] [Related]
5. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
6. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
[TBL] [Abstract][Full Text] [Related]
7. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
8. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
11. Urinary biomarkers for assessing dietary exposure to caffeine.
Crews HM; Olivier L; Wilson LA
Food Addit Contam; 2001 Dec; 18(12):1075-87. PubMed ID: 11761118
[TBL] [Abstract][Full Text] [Related]
12. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
[TBL] [Abstract][Full Text] [Related]
13. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
Kadlubar FF; Talaska G; Butler MA; Teitel CH; Massengill JP; Lang NP
Prog Clin Biol Res; 1990; 340B():107-14. PubMed ID: 2392442
[No Abstract] [Full Text] [Related]
14. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.
Kennedy MJ; Abdel-Rahman SM; Kashuba AD; Leeder JS
J Clin Pharmacol; 2004 Jul; 44(7):708-14. PubMed ID: 15199075
[TBL] [Abstract][Full Text] [Related]
15. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
[TBL] [Abstract][Full Text] [Related]
16. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.
Krul C; Hageman G
J Chromatogr B Biomed Sci Appl; 1998 May; 709(1):27-34. PubMed ID: 9653923
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of unmetabolized and phase II conjugates of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in humans: relationship to cytochrome P4501A2 and N-acetyltransferase activity.
Stillwell WG; Kidd LC; Wishnok JS; Tannenbaum SR; Sinha R
Cancer Res; 1997 Aug; 57(16):3457-64. PubMed ID: 9270013
[TBL] [Abstract][Full Text] [Related]
19. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
Jetter A; Kinzig-Schippers M; Illauer M; Hermann R; Erb K; Borlak J; Wolf H; Smith G; Cascorbi I; Sörgel F; Fuhr U
Eur J Clin Pharmacol; 2004 Mar; 60(1):17-21. PubMed ID: 14747882
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2].
Li XY; Liu YN; Li YP; Zhu JB; Yao XC; Li YF; Yang M; Yuan M; Fan XR; Yin YM
Yao Xue Xue Bao; 2014 Feb; 49(2):267-72. PubMed ID: 24761621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
